

The daily evidence digest collates recently released reports and evidence – provision of these links does not imply endorsement nor recommendation.

### **Novavax co-administered with influenza vaccines, antibody titres before and after mRNA boosters, care models for post-acute COVID-19 syndrome**

#### **Peer reviewed journals featured:**

- A systematic review on azithromycin in patients with COVID-19 [here](#)
- Randomised controlled trials of:
  - Novavax co-administered with seasonal influenza vaccines [here](#) and associated commentary [here](#)
  - Sarilumab in hospitalised adults with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1) [here](#) and associated commentary [here](#)
  - Short-term oestradiol supplementation in symptomatic postmenopausal COVID-19 females [here](#)
- A modelling study on long-term SARS-CoV-2 infections, the emergence of variants, and the risk of treatment failure [here](#)

#### **Pre-peer review articles featured:**

- Antibody titres before and after booster doses of mRNA vaccines in healthy adults [here](#)
- Care models for post-acute COVID-19 syndrome [here](#)
- Myocarditis and pericarditis following COVID-19 vaccination [here](#)
- Low neutralising antibody titres against the Mu variant in Comirnaty (Pfizer) vaccinated people [here](#)
- Effectiveness of digital contact tracing for COVID-19 in New South Wales [here](#)
- Reduced incidence of post-acute COVID-19 syndrome symptoms related to administration of COVID-19 vaccines [here](#)

#### **Guidance and reports**

- The World Health Organization published an updated COVID-19 vaccine tracker [here](#), its weekly epidemiological report on COVID-19 [here](#), and the landscape of observational studies on the effectiveness of COVID-19 vaccination [here](#)
- The Infectious Diseases Society of America published guidelines on infection prevention for healthcare personnel caring for patients with suspected or known COVID-19 [here](#)

## News and blogs

- Austria enters lockdown as cases surge across Europe [here](#)
- AstraZeneca's antibody drug AZD7442 is effective for preventing and reducing severe illness [here](#)

[Click here](#) to subscribe to the daily evidence digest.

## Living Evidence Tables

Living Evidence tables are up-to-date summaries of emerging evidence. Tables are available on [COVID-19 transmission](#), SARS-CoV-2 [vaccines](#), and [variants](#) of concern, [post-acute sequelae of COVID-19 \(PASC\)](#), [surgery and COVID-19](#), [rapid testing](#) and [risk mitigation strategies](#).